天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> Translational Oncology >>article
Translational Oncology

Translational Oncology

IF: 5
Download PDF

Etoposide, an anticancer drug involved in therapy-related secondary leukemia: Enzymes at play

Published:1 October 2021 DOI: 10.1016/j.tranon.2021.101169 PMID: 34243013
Wenchao Zhang , Panhong Gou , Jean-Marie Dupret , Christine Chomienne , Fernando Rodrigues-Lima

Abstract

Etoposide is a semi-synthetic glycoside derivative of podophyllotoxin, also known as VP-16. It is a widely used anticancer medicine in clinics. Unfortunately, high doses or long-term etoposide treatment can induce therapy-related leukemia. The mechanism by which etoposide induces secondary hematopoietic malignancies is still unclear. In this article, we review the potential mechanisms of etoposide induced therapy-related leukemia. Etoposide related leukemogenesis is known to depend on reactive oxidative metabolites of etoposide, notably etoposide quinone, which interacts with cellular proteins such as topoisomerases II (TOP2), CREB-binding protein (CREBBP), and T-Cell Protein Tyrosine Phosphatase (TCPTP). CYP3A4 and CYP3A5 metabolize etoposide to etoposide catechol, which readily oxidizes to etoposide quinone. As a poison of TOP2 enzymes, etoposide and its metabolites induce DNA double-stranded breaks (DSB), and the accumulation of DSB triggers cell apoptosis. If the cell survives, the DSB gives rise to the likelihood of faulty DNA repair events. The gene translocation could occur in mixed-lineage leukemia (MLL) gene, which is well-known in leukemogenesis. Recently, studies have revealed that etoposide metabolites, especially etoposide quinone, can covalently bind to cysteines residues of CREBBP and TCPTP enzymes, . This leads to enzyme inhibition and further affects histone acetylation and phosphorylation of the JAK-STAT pathway, thus putatively altering the proliferation and differentiation of hematopoietic stem cells (HSC). In brief, current studies suggest that etoposide and its metabolites contribute to etoposide therapy-related leukemia through TOP2 mediated DSB and impairs specific enzyme activity, such as CREBBP and TCPTP.

Substances (9)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Etoposide 33419-42-0 C29H32O13 603 suppliers $9.00-$16790.00
Podophyllotoxin 518-28-5 C22H22O8 487 suppliers $9.00-$1720.00
P450 3A4 34 suppliers Inquiry
Etoposide 3',4'-Quinone 105016-65-7 C28H28O13 19 suppliers $1075.00-$2200.00
ANTI-CBP 13 suppliers Inquiry
3',4'-dihydroxyetoposide 100007-54-3 C28H30O13 13 suppliers $135.00-$1530.00
TCPTP peptide 8 suppliers Inquiry
Cytochrome P450 3A5 (human) 7 suppliers Inquiry
MLL 5 suppliers $503.00-$503.00

Similar articles

IF:3.7

Advances in Toxicological Research of the Anticancer Drug Cisplatin

Chemical Research in Toxicology Luyu Qi, Qun Luo,etc Published: 29 July 2019
IF:7

What role does pyroptosis play in cancer?

Molecular Metabolism Chen Huang , Jian Li ,etc Published: 1 November 2022
IF:44.7

Qinghaosu (artemisinin): an antimalarial drug from China.

Science D. Klayman,etc Published: 1 November 1985